Literature DB >> 11199260

Hybrid vector designs to control the delivery, fate and expression of transgenes.

P Y Lam1, X O Breakefield.   

Abstract

One of the greatest challenges to gene therapy is the targetting of gene delivery selectively to the sites of disease and regulation of transgene expression without adverse effects. Ultimately, the successful realization of these goals is dependent upon improvements in vector design. Over the years, viral vector design has progressed from various types of replication-defective viral mutants to replication-conditioned viruses and, more recently, to 'gutted' and hybrid vectors, which have, respectively, eliminated expression of non-relevant or toxic viral genes and incorporated desired elements of different viruses so as to increase the efficacy of gene delivery in vivo. This review will focus on the different viral and cellular elements which have been incorporated into virus vectors to: improve transduction efficiencies; alter the entry specificity of virions; control the fate of transgenes in the host cells; and regulate transgene expression.

Mesh:

Substances:

Year:  2000        PMID: 11199260     DOI: 10.1002/1521-2254(200011/12)2:6<395::AID-JGM146>3.0.CO;2-K

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  3 in total

1.  A high-capacity, capsid-modified hybrid adenovirus/adeno-associated virus vector for stable transduction of human hematopoietic cells.

Authors:  Dmitry M Shayakhmetov; Cheryl A Carlson; Hartmut Stecher; Qiliang Li; George Stamatoyannopoulos; André Lieber
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Herpes simplex virus type 1/adeno-associated virus hybrid vectors.

Authors:  Anna Paula de Oliveira; Cornel Fraefel
Journal:  Open Virol J       Date:  2010-06-18

3.  Herpes simplex virus type 1/adeno-associated virus rep(+) hybrid amplicon vector improves the stability of transgene expression in human cells by site-specific integration.

Authors:  Y Wang; S M Camp; M Niwano; X Shen; J C Bakowska; X O Breakefield; P D Allen
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.